Clinical Trial Update: A Study to Determine the Safety, Pharmacokinetics, and Pharmacodynamics of DNL343 in Participants With Amyotrophic Lateral Sclerosis [Phase 1]

View source ↗

Summary

A Phase 1 study evaluating the safety, pharmacokinetics, and pharmacodynamics of DNL343 in individuals with Amyotrophic Lateral Sclerosis has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Amyotrophic Lateral Sclerosis

Drugs mentioned

• DNL343

Snippet

Sponsor: Denali Therapeutics Inc. | Conditions: Amyotrophic Lateral Sclerosis | Phase 1 | Status: COMPLETED